Skip to main content
All lobbying filings

EXECUTIVE STRATEGIES, LTD. CO.

Lobbying for SENTINEL API GROUP, INC. · Pharmaceutical Manufacturing

 Filing Registration
3rd Quarter (July 1 - Sep 30) 2025 · Florida · posted Sep 5, 2025

Official filing document

 Bills named in this filing 3
 Lobbying activity 6
Health Issues

BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.

Manufacturing

BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.

Budget/Appropriations

BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.

Pharmacy

BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.

Science/Technology

BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.

Government Issues

BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem